Drug regulators request organ-on-chip data over animal tests

Some drug regulators, including the U.S. FDA, are now asking pharmaceutical companies for preclinical data from organ-on-a-chip technology rather than relying solely on animal experiments. This marks a shift in drug development standards, as organ-on-chip platforms—microfluidic devices simulating human organ functions—are increasingly seen as viable alternatives for assessing drug safety and efficacy before human trials.

• FDA requested organ-on-chip data for a drug trial
• Organ-on-chip simulates real human organ functions
• Animal models have long dominated drug research
• Biotech firms report increased interest in these technologies